CD8A and neoplasm: However, FGFR4.8HTM.BBz-CD276.8HTM.BBz BiCisCAR, which shares the same CD8 HTM and 4-1BB CSD for both FGFR4 and CD276 CAR cassettes, only delayed tumor progression compared to mock T-cells in an RH30 orthotopic xenograft model (Supplementary Fig. 7B–F).